Wolverine Asset Management’s Myriad Genetics MYGN Stock Holding History

Wolverine Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-2,254	Closed	-$76K	–	2077
2014 Q4	$76K	Sell	2,254 -8,600	-79%	-$305K	﹤0.01%	1274
2014 Q3	$418K	Sell	10,854 -1,500	-12%	-$56K	0.01%	763
2014 Q2	$480K	Buy	12,354 +2,400	+24%	+$89.3K	0.01%	628
2014 Q1	$340K	Sell	9,954 -7,141	-42%	-$221K	0.01%	716
2013 Q4	$358K	Buy	17,095 +1,400	+9%	+$35.4K	0.01%	902
2013 Q3	$368K	Sell	15,695 -11,055	-41%	-$314K	0.01%	888
2013 Q2	$718K	Buy	+26,750	New	+$775K	0.02%	596

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BTS

BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wolverine Asset Management's MYGN Position: Q1 2015 in Review

Wolverine Asset Management sold out of Myriad Genetics (MYGN) in Q1 2015, closing a stake of 2,254 shares — an estimated $76K sold.

Wolverine Asset Management first reported a position in MYGN in Q2 2013 and held it in 7 quarters. The position peaked at $718K in Q2 2013. 251 funds tracked by Wall St. Rank hold MYGN as of Q1 2015.

Wolverine Asset Management reported no remaining Myriad Genetics position as of Q1 2015 after selling out during the quarter.
Wolverine Asset Management sold 2,254 Myriad Genetics shares in Q1 2015, an estimated $76K.
Wolverine Asset Management first reported a position in Myriad Genetics in Q2 2013 and held it in 7 quarters.
Wolverine Asset Management's Myriad Genetics position peaked at $718K in Q2 2013.
251 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2015.

Based on Wolverine Asset Management's 13F filing for Q1 2015, filed 15 May 2015.